Abstract Background: Invasive pneumococcal disease (IPD) causes significant morbidity and mortality, especially in children and older adults. Pneumococcal 7-valent and 13-valent conjugate vaccines (PCV7 and PCV13) were introduced in Taiwan in 2005 and 2011, respectively, for children. This study was conducted to evaluate the impact of PCV administered in children on adult IPD. Methods: From the logbooks of microbiology laboratories, we retrospectively retrieved Streptococcus pneumoniae isolates, collected from normally sterile sites in adult patients. One hundred and fifty-seven consecutive, nonduplicated isolates were collected from one hospital during 2001 and 2003 (pre-PCV period) and 150 isolates from three hospitals from July 2011 to June 2015 (post-PCV period). Serotypes were determined by Quellung test. Results: Among the 307 isolates, 31 serotypes/serogroups were identified. PCV7 serotypes, particularly types 14 (31.2%), 23F (19.7%) and 6B (12.7%) dominated in the pre-PCV period (78.3%) but significantly decreased in the post-PCV period (36%) (p < 0.01). PCV13 specific serotypes (PCV13ePCV7) significantly increased from 7% of the isolates in the pre-PCV period to 28.7% of the isolates in the post-PCV period (p < 0.001), particularly type 19A (from 0.6% to 10%) and 6A (from 0 to 6.7%). Serotype 15B also increased significantly from 0.6% to 6.7%
Introduction
Pneumococcal disease is a major cause of morbidity and mortality in children and elderly people. 1e3 In Taiwan, invasive Streptococcus pneumoniae infection has been a national notifiable disease since October 2007. The incidence of IPD is 3.2 per 100,000 population in adults. Case fatality rates for invasive pneumococcal disease (IPD) among all adults is 9.2% and as high as 19 .0% in adults aged >75 years. 4, 5 Pneumococcal vaccination plays an important role in the prevention of IPD. Since 2005, four types of pneumococcal vaccines have been introduced in Taiwan: the 7-valent, 10-valent, and 13-valent pneumococcal conjugate vaccines (PCV7, PCV10, and PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPV23).
6 PCV7 (Prevnar 7) and PCV10 (SYNFLORIX) have been available for use in children, primarily in the private sector since 2005 and 2010, respectively. 4 In 2011, PCV13 (Prevnar 13) was introduced and replaced PCV7 in children; also primarily in the private sector. In July 2009, PCV10 was freely provided by the government for children with conditions that placed them at high risk for IPD and children from low-income households. In March 2013, a one-dose PCV13 catch-up program was freely provided for children aged 2e5 years and a twodose PCV13 catch-up program for children aged 1 year was conducted in 2014. Since January 2015, PCV13 was included in the expanded program of immunization for children on a 2 þ 1 schedule. The first dose is given at the age of 2 months followed by a second dose after a 2-month interval, and then a booster dose at 12e15 months of age. 6 PPV-23 (Pneumovax 23) was licensed in January 1998 and has been freely provided (1 dose) for elderly people at the age of 75 years since 2007 through a nonprofit foundation. 7 According to the manufacturer's estimates, in 2010, 45.5% of children aged 2 months to 5 years in Taiwan received at least one dose of PCV7. 8 Between February 2013 and December 2013, the immunization rate for PCV13 in children aged 2e5 years increased from 31.9% to 64.2%. 9 With the increased uptake rate of PCV in children in Taiwan, childhood IPD caused by PCV-specific serotypes has continuously decreased. 9 In addition to the vaccine-targeted population (i.e., infants and young children), indirect protection from PCV7 serotypes has been observed in adult IPD and pneumonia cases in England as well as in the United States. 10, 11 Whether partial coverage of PCV in Taiwanese children (primarily through the private market), with transitions to higher valence conjugate vaccines, provides indirect protection in adults merits further exploration. We present a hospital-based study to evaluate the impact of PCV on serotype distribution of adult IPD in Taiwan.
Materials and methods
From the logbooks of microbiology laboratories, we retrospectively identified adult patients (>18 years old) with IPD, from whom S. pneumoniae was isolated from normally sterile sites including blood, cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, and synovial fluid in Chang Gung Memorial Hospital Network (CGMH), Taiwan. 12 One hundred and fifty-seven consecutive, nonduplicated isolates (1 isolate from a single patient) were collected and retrieved from one CGMH center only (Linkou Medical Center) between 2001 and 2003 (pre-PCV period) and 150 consecutive, nonduplicated isolates from three CGMH centers (Linkou, Kaohsiung, and Keelung) between July 2011 and June 2015 (post-PCV period). All isolates were sent to Linkou Medical Center for serotype testing. We retrospectively reviewed the medical record of each patient to retrieve their demographic and clinical characteristics.
S. pneumoniae was identified by standard methods. 13 The serotype of each pneumococcal isolate was determined by the Quellung reaction using commercialized antisera (Statens Serum Institut, Copenhagen, Denmark 
Results
During the study period, a total of 307 isolates of S. pneumoniae were identified and collected; 157 isolates from the pre-PCV period and 150 isolates from the post-PCV period. During the post-PCV period, 86 isolates were collected from Linkou Medical Center, 33 isolates from Kaohsiung Center, and 31 isolates from Keelung Branch Hospital. Of the 307 patients, 70% were male and the mean age was 59.6 years.
More than 40% of the patients were 65 years of age. Detailed demographic data are shown in Table 1 . Two hundred and eighty-five isolates (92.8%) were identified from the bloodstream. Other sources were less common and included CSF (n Z 10), pleural fluid (n Z 8), synovial fluid (n Z 1), and peritoneal fluid (n Z 3). The detailed source distribution of isolates identified in each year is listed in Table 2 .
Of the 307 isolates, a total of 31 serogroups/serotypes were identified. The major serotypes of S. pneumoniae during the pre-PCV period were types 14 (31.2%), 23F (19.7%), 6B (12.7%), 9V (7.0%), 19F (6.4%), and 3 (6.4%) ( Table 3) . During the post-PCV period, the major serotypes were types 14 (14.7%), 3 (10.7%), 19A (10%), 23A (8%), and 6A, 6B, and 15B (each 6.7%). Comparing both periods, we found that Serotypes 9V, 14, and 23F significantly decreased, while Serotypes 6A, 15A, 15B, 19A, and 23A significantly increased.
PCV7 serotypes dominated during the pre-PCV period and accounted for 123 (78.3%) isolates but significantly decreased during the post-PCV period, accounting for 54 (36%) isolates only. PCV13 serotypes accounted for 134 (85.3%) isolates during the pre-PCV period and 97 (64.7%) isolates during the post-PCV period. PPV-23 isolates accounted for 139 (88.4%) isolates during the pre-PCV period and 107 (71.3%) isolates during the post-PCV period. Nonvaccine serotypes increased significantly from 18 (11.5%) isolates in the pre-PCV period to 33 (22.0%) isolates in the post-PCV period (p < 0.05) ( Table 3 ).
The absolute number of cases caused by PCV7, PCV13, and PPV23 serotypes decreased during the post-PCV period. However, the additional serotypes in PCV13 (PCV13ePCV7) significantly increased from 7% of the isolates during the pre-PCV period to 28.7% of the isolates during the post-PCV period (p < 0.001). In particular, serotype 19A increased from one (5.3%) isolate in 2011 to five (11.9%) isolates in 2012 (Supplementary Table 1 ). This trend may be slowing after the introduction of PCV13 in children; Serotype 19A decreased from four (11.4%) isolates in 2013 to two (9.1%) isolates in 2015. However, the data must be interpreted with caution due to the small sample size included in the study.
The additional serotypes in PPV23 (PPV23ePCV13) also increased significantly from five (3.2%) isolates in the pre-PCV period to 20 (13.3%) isolates in the post-PCV period (p < 0.05). Serotype 15B increased significantly from 0.6% of isolates during the pre-PCV period to 6.7% of the isolates during the post-PCV period (p Z 0.005), particularly in 2015 when it accounted for 22.7% of all isolates.
Among nonvaccine serotypes, 23A increased from 3.2% of all isolates during the pre-PCV period to 8% of all isolates in the post-PCV period, particularly in 2012 when it accounted for 14.3% of all isolates. Serotype 15A significantly increased from zero isolates in the pre-PCV period to seven (4.7%) isolates in the post-PCV period (p < 0.05).
Discussion
Results from the present study show that in Taiwan, PCV7 serotypes, particularly 14, 23F, and 6B, accounted for nearly 80% of isolates during the pre-PCV period. In the post-PCV period, the distribution of serotypes was more diverse. Only three serotypes each, including 14, 3, and 19A, accounted for at least 10% of isolates. PCV7-containing serotypes significantly decreased, accounting for only 36% of the isolates. These findings indicate that there may be herd immunity induced by PCV vaccination in children, even in a country that has transitioned from lower valence to higher valence vaccines, and from partial coverage in the private sector to national coverage through the routine immunization program.
After the introduction of PCV, the incidence of vaccinetype IPD in children significantly decreased in western countries, 9, 10, 14, 15 as well as in Taiwan. 8 In addition to the PCV-targeted population, indirect protection from PCV7 serotypes was also observed in adult IPD and pneumonia cases in western countries. 10, 11, 16 In this study, the number of adult IPD cases in Linkou Center decreased from 157 cases during a 3-year period, 5.29 cases per 10,000 hospitalized patients, in the pre-PCV era to 86 cases during a 4-year period, 1.70 cases per 10,000 hospitalized patients in the post-PCV era, which indicates a significant reduction in adult IPD cases in Taiwan between the two study periods based on data from our hospitals.
Incorporating data from adult patients in three large studies (Table 4) in Taiwan, we found that IPD cases due to serotypes contained in available vaccines had declined overall since 2001. However, as shown in the present study, following the introduction of PCV7, additional serotypes in PCV13 (PCV13ePCV7) specifically 6A and 19A, additional serotypes in PPV23 (PPV23ePCV13) specifically 15B, as well as nonvaccine Serotypes 15A and 23A also significantly increased from the pre-PCV period to the post-PCV period. The significant increase of serotype 19A may be related to the selection of nonvaccine serotypes after PCV7 introduction, clonal expansion of sequence type (ST) 320 and multiple drug resistance of serotype 19A. 18e21 The increase in serotype 6A and other non-PCV7 serotypes may primarily be the result of serotype replacement following PCV7 administration, which was also observed in other countries. 22 Of note, PCV7 serotypes 19F and 6B decreased from the pre-PCV period to post-PCV period but the decrease did not reach statistical significance. This finding may be related to the relatively high colonization rates for both serotypes in PCV immunized children, 23 with a subsequent higher possibility of transmission to the adult population. In contrast, PCV13-specific serotype 3 increased during the study periods but the increase did not reach statistical significance and needs further observation after PCV13 implementation.
There were several limitations to the present study. First, since this was a hospital-based study, results may not be generalizable to all adult IPD cases before and after the introduction of PCV in Taiwan. Second, since the total number of adult IPD cases decreased during the post-PCV period, we had to recruit cases from two additional hospitals during this period for the comparison.
In summary, serotype distribution of adult IPD cases in Taiwan has evolved since the introduction of PCV in children. The prevalence of PCV7 serotypes (particularly 9V, 14, and 23F) declined, while other vaccine serotypes (19A, 6A, and 15B) and nonvaccine serotypes (15A and 23A) have increased. An indirect impact of childhood vaccination was observed in adults in Taiwan, even in the context of incremental expansion of the childhood vaccination program, and transitions to higher-valence pneumococcal vaccines. Continuous surveillance after the PCV13 vaccination program in children is needed.
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